Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal

Review OA: closed
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-09 ⓘ

This review appraises the role of autoimmunity in premature ovarian insufficiency, noting that autoimmune cases are clinically indistinguishable from others and highlighting a lack of reliable diagnostic tests or standardized treatment guidelines.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE: Primary ovarian insufficiency (POI) represents ovarian dysfunction related to very early aging of the ovaries. While the cause of POI in a majority of clinical cases remains undefined, autoimmunity is responsible for approximately 4-30% of POI cases. In the present paper, we aim to provide a critical appraisal and update review on the role of autoimmunity in POI patients. METHODS: A literature review was conducted for all relevant articles reporting on POI and autoimmunity. PubMed/MEDLINE and the Cochrane library were searched for the best available evidence on this topic. RESULTS: Patients with POI and coexisting autoimmunity are indistinguishable from those with negative autoimmune screen with regard to age of onset, prevalence of primary amenorrhea, or their endocrine profiles. A specific noninvasive reliable diagnostic test for the diagnosis of an autoimmune etiology is lacking; therefore, patients should be screened for the most common autoantibodies, i.e., steroid cell antibodies, anti-ovarian antibodies, and anti-thyroid antibodies. Moreover, treatment strategies to POI infertility are lacking and controversial. CONCLUSIONS: Nowadays, guidelines for the treatment of autoimmune POI are not available. Moreover, since diagnostic and treatment strategies to POI infertility are still lacking and controversial, further large clinical studies are needed to investigate the true impact of autoimmunity on POI and to identify the selected groups of patients who are most likely to benefit from immunossuprresive treatment.

My notes (saved in your browser only)

MeSH descriptors

Autoimmunity Primary Ovarian Insufficiency Autoantibodies Autoantibodies Autoimmunity Female Humans Infertility Infertility Primary Ovarian Insufficiency

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-10-25T09:32:14.900964+00:00
pubmed
last seen: 2026-10-08T21:25:22.513924+00:00
unpaywall
last seen: 2026-10-26T06:31:53.434635+00:00